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Background: Medication adherence is critical for the management of chronic disorders such as cardiovascular (CV) disease. However, long-term 
adherence has not been well described in acute coronary syndrome (ACS) patients.
methods: ACS patients hospitalized with an ICD-9 code for acute myocardial infarction (MI) or unstable angina were identified from the HealthCore 
Integrated Research Database (HIRDSM) between Jan 2006 and Sept 2011. Mean medication possession ratios (MPR) for guideline-recommended 
ACS treatments were assessed 1 and 3 years after the index ACS using pharmacy claims data, stratified by presence or absence of recurrent CV 
events, defined as stroke, MI or CHD-related mortality.
results: Of 140,903 ACS patients identified, 22% had >1 recurrent CV events and were on average older (72.4 vs 65.2 years), included more 
women (44.5 vs 40.6%), and had more comorbidities (e.g. diabetes mellitus 49.7 vs 39.7%) as compared to those without recurrent events. After 3 
years, patients were most adherent to antihypertensives (MPR=0.70) and least adherent to anticoagulants (MPR=0.41). Overall, differences in MPRs 
in patients with vs without recurrent events were small, although some were statistically significant. 
Total patients Patients with recurrent CV events* Patients without recurrent CV events*
n (%) Mean MPR (SD) n (%) Mean MPR (SD) n (%) Mean MPR (SD) P-values†
Antihypertensives
MPR at 1 yr
MPR at 3 yrs
56,575 (66.5)
23,808 (67.0)
0.79 (0.27)
0.70 (0.30)
12,704 (67.0)
6,020 (67.5)
0.81 (0.25)
0.74 (0.28)
43,871 (66.3)
17,788 (66.8)
0.79 (0.28)
0.69 (0.31)
<0.0001
<0.0001
Statins
MPR at 1 yr
MPR at 3 yrs
42,787 (50.3)
17,705 (49.8)
0.71 (0.28)
0.60 (0.31)
9,275 (48.9)
4,335 (48.6)
0.70 (0.28)
0.60 (0.30)
33,512 (50.7)
13,370 (50.2)
0.71 (0.28)
0.60 (0.31)
<0.001
NS
Other antidyslipidemics
MPR at 1 yr
MPR at 3 yrs
11,379 (13.4)
5,325 (15.0)
0.68 (0.30)
0.54 (0.32)
2,462 (13.0)
1,323 (14.8)
0.67 (0.30)
0.53 (0.32)
8,917 (13.5)
4,002 (15.0)
0.69 (0.30)
0.54 (0.33)
<0.01
NS
Antiplatelets
MPR at 1 yr
MPR at 3 yrs
33,973 (39.9)
14,572 (41.0)
0.72 (0.31)
0.56 (0.33)
8,409 (44.3)
4,091 (45.9)
0.71 (0.30)
0.57 (0.32)
25,564 (38.7)
10,481 (39.4)
0.73 (0.31)
0.56 (0.33)
<0.0001
NS
Anticoagulants
MPR at 1 yr
MPR at 3 yrs
7,453 (8.8)
3,089 (8.7)
0.54 (0.30)
0.41 (0.31)
2,143 (11.3)
926 (10.4)
0.55 (0.29)
0.44 (0.30)
5,310 (8.0)
2,163 (8.1)
0.54 (0.30)
0.41 (0.31)
NS
<0.05
NS=not significant; MPR=total number of days’ supply/duration of follow-up; SD=standard deviation. n (%) reflects total (%) patients who have a pharmacy claim between index ACS 
discharge date (up to 90 days following discharge) through the end of the year.
*Recurrent CV event defined as occurrence of stroke, MI or CHD-related mortality after the index ACS event.
†Statistical comparison between MPR in the recurrent and non-recurrent group. P values <0.05 were considered significant and were determined using T-test to compare means and 
Chi-square test to compare frequencies.
conclusion: At 3 years, medication adherence was highest to antihypertensives and lowest to anticoagulants. The gaps in adherence highlight the need 
to encourage and monitor treatment use following ACS, as well as understand class-specific adherence barriers, to improve long-term outcomes.
